Skip to main content

Transurethral Incision with Transverse Mucosal Realignment (TUITMR)

Transurethral incision with transverse mucosal realignment (TUITMR) is a novel endoscopic technique described by Abramowitz et al. that functions as a cystoscopic Y-V plasty for the treatment of bladder neck contracture (BNC) and vesicourethral anastomotic stenosis (VUAS), achieving 89% success after a single procedure and 100% after a second procedure, with no de novo incontinence.[1] A 2025 review in the Journal of Endourology highlights TUITMR alongside drug-coated balloon dilation as one of the key recent advances in minimally invasive posterior urethral stenosis management, with both techniques demonstrating short-term success rates of 85–90%, significantly outperforming traditional DVIU/dilation (40–72%).[2]

Conceptual Rationale​

The fundamental problem with traditional endoscopic incision (DVIU/TUIBNC) is that after the scar is incised, the wound heals by secondary intention — epithelium must migrate across the exposed scar bed, and if fibrosis outpaces re-epithelialization, the contracture recurs. TUITMR addresses this by bringing healthy bladder mucosa across the incised defect, analogous to how an open Y-V plasty advances a flap of healthy tissue into the stenotic segment. This ensures that the incision site is covered by viable mucosa rather than relying on secondary wound healing over scar tissue.[1][2]

Step-by-Step Surgical Technique​

Based on the original description by Abramowitz et al.:[1]

  1. Access and assessment: Cystoscopy is performed to identify the stenotic segment. A guidewire is passed through the contracture into the bladder for safety.
  2. Dilation: The contracture is dilated (typically with a balloon dilator) to allow passage of the resectoscope/cystoscope.
  3. Incision of the scar: The scar tissue at the bladder neck or vesicourethral anastomosis is incised cystoscopically — similar to a standard TUIBNC — creating a longitudinal incision through the stenotic segment. This opens the narrowed lumen.
  4. Transverse mucosal realignment (the key step): Endoscopic access is established with the JNW UrTrac sheath, and the RD180 suturing device (LSI Solutions) is introduced transurethrally to pass 2-0 monofilament through the stenotic scar and adjacent healthy bladder mucosa. Sutures are secured with the Ti-Knot fastener, eliminating the need for intracorporeal knot-tying. Healthy bladder mucosa from the proximal (bladder) side of the incision is advanced across the defect in a transverse orientation, effectively covering the incised scar bed with viable mucosa. This is the endoscopic equivalent of the flap advancement in an open Y-V plasty — the "Y" incision is converted to a "V" closure by advancing the mucosal flap distally.[1]
  5. Catheter placement: A urethral catheter is left in place postoperatively.
  6. Follow-up: Cystoscopic evaluation at 4 months to confirm patency, defined as the ability to pass a 17 Fr flexible cystoscope through the previously stenotic segment.[1]

Published Outcomes​

The only published series to date is the index study by Abramowitz et al. (2021):[1]

ParameterResult
Number of patients19
Etiology53% VUAS, 47% BNC
Prior pelvic radiation32%
Study periodJuly 2019 – December 2020
Median follow-up6 months
Success after 1 procedure89% (17/19)
Success after 2 procedures100% (19/19)
De novo incontinence0%
Major complicationsNone

Comparison to Other Endoscopic Techniques​

TechniqueSingle-Procedure SuccessCumulative SuccessDe Novo SUIKey Limitation
TUITMR89%100%0%Small series, short follow-up, single surgeon[1]
Standard TUIBNC (deep lateral)72–82%86–94%12–31%Relies on secondary healing over scar[2][3]
DVIU + Mitomycin C65%90%Variable7% serious AE rate; conflicting data[4]
Drug-coated balloon (Optilume)59–76% (anatomic/functional)EvolvingLowLimited long-term data; variable by stricture type[5][6]
Robotic Y-V plasty83–100%90%0–24% (higher in VUAS)Requires robotic platform; longer OR time[7][8]
Robotic transvesical BNR91%—0%Small series (n=11)[10]

Advantages​

  • Addresses the root cause of failure: By covering the incision with healthy mucosa, TUITMR prevents the cycle of scar re-formation that plagues traditional DVIU/incision.[1][2]
  • No de novo incontinence: Unlike standard TUIBNC (which carries 12–31% de novo SUI risk), TUITMR had 0% de novo incontinence in the initial series.[1]
  • Entirely endoscopic: Unlike robotic Y-V plasty (which achieves similar conceptual goals), TUITMR avoids the need for abdominal access, port placement, or robotic platform, potentially reducing morbidity, operative time, and cost.[1]
  • Applicable to radiated patients: 32% of the initial cohort had prior pelvic radiation, a population known to have worse outcomes with traditional endoscopic approaches.[1][5]
  • Avoids adjunctive agents: No need for mitomycin C or corticosteroid injections, eliminating the risk of associated complications (e.g., osteitis pubis, fistula, need for cystectomy reported with MMC).[1]

Limitations and Caveats​

  • Single-surgeon, single-institution experience with only 19 patients — reproducibility at other centers has not yet been established.[1]
  • Short follow-up (median 6 months) — long-term durability beyond 1 year is unknown. BNC/VUAS recurrences can occur late, and meta-analysis of endoscopic VUAS treatment shows that 90% of patients require repeat intervention within 2 years with traditional techniques.[2][11]
  • Technical demands: The procedure requires facility with transurethral suturing using a laparoscopic suturing platform — typically the RD180 and Ti-Knot deployed through the JNW UrTrac sheath — which is not a standard skill for most urologists. The learning curve has not been characterized.[1]
  • No comparative data: No head-to-head comparison with standard TUIBNC, DVIU + MMC, drug-coated balloon, or robotic Y-V plasty exists.[12]
  • Success definition: Patency was defined anatomically (17 Fr cystoscope passage) at 4 months — functional outcomes (uroflowmetry, symptom scores) were not reported in detail.[1]

Where TUITMR Fits in the Treatment Algorithm​

Based on the available evidence and the AUA guideline framework:[12]

  1. First-time BNC/VUAS → Standard TUIBNC or TUITMR (if expertise available) are both reasonable first-line options.
  2. First recurrence → Repeat endoscopic treatment is justified; TUITMR may offer an advantage over repeat standard incision by addressing the mucosal coverage problem.
  3. Recalcitrant disease (≥2 failed endoscopic treatments) → TUITMR, DVIU + MMC, drug-coated balloon, or referral for robotic/open reconstruction.[12]
  4. Radiated patients → TUITMR may be particularly appealing given the poor outcomes of traditional endoscopic approaches in this population (76% success with MMC vs 94% nonradiated).[5]

Emerging Context: Drug-Coated Balloon as a Competing Innovation​

A 2025 real-world comparative study of 141 patients found that drug-coated balloon (DCB) dilation with Optilume significantly improved recurrence-free survival compared to standard endoscopic treatment (HR 0.40, p = 0.021).[6] However, a larger TURNS multi-institutional study of 319 patients (59 with posterior urethral stenosis) showed more modest results, with 1-year anatomical recurrence-free survival of only 59.4% for posterior stenoses.[7] Both TUITMR and DCB represent conceptually different approaches to the same problem — TUITMR provides mucosal coverage while DCB delivers local paclitaxel to inhibit fibroblast proliferation — and head-to-head comparison data are lacking.[2]

Summary​

TUITMR represents a conceptually elegant advance in the endoscopic management of BNC and VUAS by translating the principles of open Y-V plasty into a fully endoscopic procedure. The initial results are highly promising — particularly the absence of de novo incontinence and the high single-procedure success rate even in radiated patients. However, the evidence base remains limited to a single small retrospective series with short follow-up. Multi-institutional validation, longer-term outcomes, and comparative studies are needed before TUITMR can be considered a standard-of-care option.[1][2]

References​

1. Abramowitz DJ, Balzano FL, Ruel NH, Chan KG, Warner JN. "Transurethral Incision With Transverse Mucosal Realignment for the Management of Bladder Neck Contracture and Vesicourethral Anastomotic Stenosis." Urology. 2021;152:102-108. doi:10.1016/j.urology.2021.02.035

2. Hudson CN, Damm T, Monn MF. "Minimally Invasive Treatments for Posterior Urethral Stenosis." Journal of Endourology. 2025. doi:10.1177/08927790251371037

3. Nealon SW, Bhanvadia RR, Badkhshan S, et al. "Transurethral Incisions for Bladder Neck Contracture: Comparable Results Without Intralesional Injections." Journal of Clinical Medicine. 2022;11(15):4355. doi:10.3390/jcm11154355

4. Ramirez D, Zhao LC, Bagrodia A, et al. "Deep Lateral Transurethral Incisions for Recurrent Bladder Neck Contracture: Promising 5-Year Experience Using a Standardized Approach." Urology. 2013;82(6):1430-5. doi:10.1016/j.urology.2013.08.018

5. Rozanski AT, Zhang LT, Holst DD, et al. "The Effect of Radiation Therapy on the Efficacy of Internal Urethrotomy With Intralesional Mitomycin C for Recurrent Vesicourethral Anastomotic Stenoses and Bladder Neck Contractures: A Multi-Institutional Experience." Urology. 2021;147:294-298. doi:10.1016/j.urology.2020.09.035

6. Berg EK, Mehmedovic S, Askari D, et al. "Efficacy of Drug-Coated Balloon Dilation vs. Endoscopic Standard Treatment in Posterior Urethral Stenosis: A Real-World Comparative Study." Urology. 2025. doi:10.1016/j.urology.2025.07.034

7. Patel HV, Erickson BA, Abbasi B, et al. "Early Real-World Experience With Optilume® Drug-Coated Balloon for Anterior Urethral Strictures and Posterior Urethral Stenoses." Urology. 2025. doi:10.1016/j.urology.2025.10.025

8. Viegas V, Freton L, Richard C, et al. "Robotic YV Plasty Outcomes for Bladder Neck Contracture vs. Vesico-Urethral Anastomotic Stricture." World Journal of Urology. 2024;42(1):172. doi:10.1007/s00345-024-04814-8

9. Abo Youssef N, Obrecht F, Padevit C, Brachlow J, John H. "Short and Intermediate-Term Outcome of Robot-Assisted Inverted YV-Plasty for Recurrent Bladder Neck Stenosis – A Single Centre Study." Urology. 2023;175:196-201. doi:10.1016/j.urology.2023.02.011

10. Lee M, Lesgart M, McPartland C, Lee R, Eun DD. "Robotic Transvesical Bladder Neck Reconstruction: A Novel Approach to Managing Vesicourethral Anastomotic Stenosis." European Urology. 2025. doi:10.1016/j.eururo.2025.04.026

11. Delchet O, Nourredine M, González Serrano A, et al. "Post-Prostatectomy Anastomotic Stenosis: Systematic Review and Meta-Analysis of Endoscopic Treatment." BJU International. 2024;133(3):237-245. doi:10.1111/bju.16141

12. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. "Urethral Stricture Disease Guideline Amendment (2023)." The Journal of Urology. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482